CSF Levels of the Endocannabinoid Anandamide are Reduced in Patients with Untreated Narcolepsy Type 1: A Pilot Study.

CNS & Neurological Disorders Drug Targets
Andrea RomigiM Maccarrone

Abstract

Endocannabinoids (ECs) modulate both excitatory and inhibitory components in the CNS. There is a growing body of evidence that shows ECs influence both hypothalamic orexinergic and histaminergic neurons involved in narcolepsy physiopathology. Therefore, ECs may influence sleep and sleep-wake cycle. To evaluate EC levels in the CSF of untreated narcoleptic patients to test whether ECs are dysregulated in Narcolepsy Type 1 (NT1) and Type 2 (NT2). We compared CSF Anandamide (AEA), 2-Arachidonoylglycerol (2-AG) and orexin in narcoleptic drug-naïve patients and in a sample of healthy subjects. We compared NT1 (n=6), NT2 (n=6), and healthy controls (n=6). We found significantly reduced AEA levels in NT1 patients compared to both NT2 and controls. No differences were found between AEA levels in NT2 versus controls and between 2-AG levels in all groups, although a trend toward a decrease in NT1 was evident. Finally, the CSF AEA level was related to CSF orexin levels in all subjects. We demonstrated that the EC system is dysregulated in NT1.

References

May 1, 2008·Nature Reviews. Drug Discovery·Vincenzo Di Marzo
Sep 5, 2009·Trends in Pharmacological Sciences·Angelo A IzzoRaphael Mechoulam
Jan 10, 2013·The International Journal of Neuropsychopharmacology·Alline C CamposFrancisco S Guimarães
Apr 23, 2013·Pharmacology, Biochemistry, and Behavior·Marcel Pérez-MoralesOscar Prospéro-García
Mar 19, 2014·Journal of Sleep Research·Claudio LiguoriAndrea Romigi
Jul 29, 2015·British Journal of Pharmacology·R B LaprairieE M Denovan-Wright
Dec 31, 2015·The New England Journal of Medicine·Thomas E Scammell
Jan 25, 2016·Sleep & Breathing = Schlaf & Atmung·Claudio LiguoriAndrea Romigi
Mar 30, 2016·Annual Review of Neuroscience·Natalie E Zlebnik, Joseph F Cheer
Oct 21, 2016·Neuroscience and Biobehavioral Reviews·Oscar Prospéro-GarcíaMónica Méndez-Díaz
Feb 25, 2017·Pharmacology & Therapeutics·Simona PisantiMaurizio Bifulco
Feb 28, 2017·CNS & Neurological Disorders Drug Targets·Eric Murillo-RodriguezMiriel de-la-Cruz
Apr 18, 2017·CNS & Neurological Disorders Drug Targets·Renata SoliminiRoberta Pacifici
Apr 18, 2017·CNS & Neurological Disorders Drug Targets·Giovanni MartinottiOrnella Corazza
May 21, 2017·Current Opinion in Neurobiology·Jozelia Gomes Pacheco FerreiraAntoine Adamantidis
Aug 30, 2017·CNS & Neurological Disorders Drug Targets·Simona Pichini, Francesco P Busardo
Mar 16, 2018·CNS & Neurological Disorders Drug Targets·Oscar Arias-CarrionEric Murillo-Rodriguez
Aug 28, 2018·Neurobiology of Disease·Fumito NaganumaRamalingam Vetrivelan
Dec 28, 2018·Psychiatry and Clinical Neurosciences·Claudio LiguoriFabio Placidi
Dec 28, 2018·CNS & Neurological Disorders Drug Targets·Mirna Rossi Barbosa MedeirosRenato Sobral Monteiro-Junior
Mar 27, 2019·Lancet Neurology·Daniel FriedmanMauro Maccarrone
Jun 28, 2019·CNS & Neurological Disorders Drug Targets·Maria Lia LunardelliSalvatore Cuzzocrea
Jul 19, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Claudia Calpe-LópezMaria A Aguilar

❮ Previous
Next ❯

Related Concepts

Related Feeds

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.